AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIB (RESTORE SR IIB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00571779|
Recruitment Status : Withdrawn
First Posted : December 12, 2007
Last Update Posted : February 21, 2011
Information provided by:
Feasibility study arm to evaluate the safety of adding the left atrial linear connecting lesions of the Cox-Maze lesion set to the current RESTORE SR II IDE study procedure of performing pulmonary vein isolation, selected left atrial autonomic ganglionated plexi (GP) ablation, and optional left atrial appendage (LAA) excision/exclusion on a beating heart for patients with permanent or persistent Atrial Fibrillation (AF).
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Device: AtriCure Bipolar System||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation|
Primary Outcome Measures :
- Feasibility of performing the operation by demonstrating the ability to consistently isolate the left and right pulmonary veins and to confirm conduction block across the roof, anterior and LAA linear lesions.
- The primary safety endpoint will be determined by assessing the rate of serious adverse events.
No Contacts or Locations Provided